stay updated

Explore the latest news from Khondrion and its team.

Khondrion press releases

November 27, 2020

Khondrion shares progress of sonlicromanol development programme at Mitochondrial Medicine 2020 virtual conference

Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the...

October 7, 2020

Khondrion to present at Mitocon’s 10th Italian Meeting on Mitochondrial Diseases

Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that...

October 1, 2020

Khondrion announces new Scientific Advisory Board

Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that it has...

September 28, 2020

Khondrion Receives Rare Pediatric Disease Designation for Sonlicromanol from US FDA

Designation granted for the treatment of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes) syndrome. Khondrion, a...

July 1, 2020

Khondrion appoints Herma Renkema as Chief Early Development Officer

NIJMEGEN, the Netherlands – Wednesday July 1st, 2020 Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies...

April 15, 2020

Khondrion highlights potential role of inflammatory lipid modulator prostaglandin E2 in COVID-19 disease

Khondrion highlights potential role of inflammatory lipid modulator prostaglandin E2 in COVID-19 disease and proposes potential...

our stories

October 31, 2015

Khondrion welcomes Hans Schikan

Khondrion Welcomes Hans Schikan, Former Prosensa CEO, to Advisory Board August 10, 2015, NIJMEGEN – Khondrion, the Dutch...